Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

Jan. 15, 2025 — Scientists have come up with a drug that is a potential candidate for tackling memory deficits in the early stages of the disease in rodents. ... New Innovative Local Treatment ...

Shares of Novavax declined after the company reaffirmed full-year revenue and fellow vaccine maker Moderna lowered its guidance. Novavax stock was down 7.3%, to $8.64, on Monday but is up about 89% ...

CureVac shares have been volatile over the past week, gaining some 25%. The stock has seen increased trading volume following the U.S.'s first human death from H5N1 bird flu. Get Real-Time News ...

Leerink Partners has recently reduced CureVac BV (CVAC) stock to Market Perform rating, as announced on April 25, 2024, according to Finviz. Earlier, on June 8, 2023, SVB Securities had initiated the ...

Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you. Daily news – Get the most important news from ...

Lilly has signed a deal with CureVac to develop up to five next-generation cancer vaccines which use messenger RNA (mRNA) technology. While previous cancer vaccines approaches have disappointed ...

CureVac (NASDAQ:CVAC) was able to report positive data from Part A of its phase 1 study using its vaccine candidate CVGBM for the treatment of patients with HLA-*02:01-positive patients with newly ...

We recently published a list of 10 Firms Post Strong Gains Amid Wall Street Bloodbath. In this article, we are going to take ...

Shares in vaccine developers jumped on Tuesday after the US reported its first human death from the H5 strain of bird flu.